100050 1400W - CAS 214358-33-5 - Calbiochem

100050
Cenu nelze zjistit
Minimum Quantity needs to be mulitiple of
S dokončenou objednávkou Další informace
Ušetřili jste ()
 
Vyžádat nacenění
Omezená dostupnostOmezená dostupnost
Na skladě 
Přerušeno
Dostupné omezené množství
Dostupnost bude potvrzena
    Remaining : Will advise
      Remaining : Will advise
      Bude poskytnuto
      Kontaktujte Zákaznický servis
      Contact Customer Service
      Zobrazit ceny a dostupnost
      Klikněte pro vytištění této stránky

      Přehled

      Replacement Information

      Tabulka spec. kláve

      Empirical FormulaCAS #
      C₁₀H₁₅N₃ · 2HCl 214358-33-5

      Ceny a dostupnost

      Katalogové čísloDostupnost Balení ks/bal. Cena Množství
      100050-5MG
      Zjišťuji dostupnost...
      Omezená dostupnostOmezená dostupnost
      Na skladě 
      Přerušeno
      Dostupné omezené množství
      Dostupnost bude potvrzena
        Remaining : Will advise
          Remaining : Will advise
          Bude poskytnuto
          Kontaktujte Zákaznický servis
          Contact Customer Service

          Plastová ampulka 5 mg
          Zjišťuji cenu...
          Cenu nelze zjistit
          Minimum Quantity needs to be mulitiple of
          S dokončenou objednávkou Další informace
          Ušetřili jste ()
           
          Vyžádat nacenění
          Description
          OverviewA selective, cell-permeable, irreversible, slow, tight-binding inhibitor of inducible nitric oxide synthase (iNOS; Kd = 7 nM). Suitable for use in both in vitro and in vivo systems. Has a protective effect against cerebral ischemia by reducing ischemic lesion volumes. Exhibits greater than 5000- and 200-fold potency against human iNOS relative to eNOS and nNOS, respectively, and greater than 1000-fold potency against rat iNOS relative to eNOS.
          Catalogue Number100050
          Brand Family Calbiochem®
          SynonymsN-(3-Aminomethyl)benzylacetamidine, 2HCl
          References
          ReferencesParmentier, S., et al. 1999. Br. J. Pharmacol. 127, 546.
          Cardenas, A., et al. 1998. Eur. J. Pharmacol. 354, 161.
          Parrino, P.E., et al. 1998. Ann. Thorac. Surg. 66, 733.
          Garvey, E.P., et al. 1997. J. Biol. Chem. 272, 4959.
          Laszlo, F., and Whittle, B.J. 1997. Eur. J. Pharmacol. 334, 99.
          Thomsen, L.L., et al. 1997. Cancer Res. 57, 3300.
          Product Information
          CAS number214358-33-5
          ATP CompetitiveN
          FormWhite solid
          Hill FormulaC₁₀H₁₅N₃ · 2HCl
          Chemical formulaC₁₀H₁₅N₃ · 2HCl
          Hygroscopic Hygroscopic
          ReversibleN
          Structure formula ImageStructure formula Image
          Applications
          Biological Information
          Primary TargetiNOS
          Primary Target IC<sub>50</sub>Kd = 7 nM against inducible nitric oxide synthase (iNOS)
          Purity≥95% by HPLC
          Physicochemical Information
          Cell permeableY
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Ambient Temperature Only
          Toxicity Standard Handling
          Storage -20°C
          Hygroscopic Hygroscopic
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable up to 3 months at -20°C.
          Packaging Information
          Packaged under inert gas Packaged under inert gas
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          MSDS

          Title

          Safety Data Sheet (SDS) 

          Certificates of Analysis

          TitleLot Number
          100050

          References

          Přehled odkazů
          Parmentier, S., et al. 1999. Br. J. Pharmacol. 127, 546.
          Cardenas, A., et al. 1998. Eur. J. Pharmacol. 354, 161.
          Parrino, P.E., et al. 1998. Ann. Thorac. Surg. 66, 733.
          Garvey, E.P., et al. 1997. J. Biol. Chem. 272, 4959.
          Laszlo, F., and Whittle, B.J. 1997. Eur. J. Pharmacol. 334, 99.
          Thomsen, L.L., et al. 1997. Cancer Res. 57, 3300.

          Brochure

          Title
          Nitric Oxide and Oxidative Stress Brochure
          Pathways and Biomarkers of Oxidative Stress

          Citations

          Název
        • Peyssonnaux, C., et al. 2005. The Journal of Clinical Investigation 115, 1860.
        • Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision04-April-2011 RFH
          SynonymsN-(3-Aminomethyl)benzylacetamidine, 2HCl
          DescriptionA selective, irreversible, slow, tight binding inhibitor of inducible nitric oxide synthase (iNOS, Kd = 7 nM) both in vitro and in vivo. Has a protective effect against cerebral ischemia by reducing ischemic lesion volumes. Exhibits greater than 5000- and 200-fold potency against human iNOS relative to eNOS and nNOS, respectively, and greater than 1000-fold potency against rat iNOS relative to eNOS.
          FormWhite solid
          Intert gas (Yes/No) Packaged under inert gas
          CAS number214358-33-5
          Chemical formulaC₁₀H₁₅N₃ · 2HCl
          Structure formulaStructure formula
          Purity≥95% by HPLC
          SolubilityMethanol (5 mg/ml) or H₂O (1 mg/ml)
          Storage -20°C
          Hygroscopic
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable up to 3 months at -20°C.
          Toxicity Standard Handling
          ReferencesParmentier, S., et al. 1999. Br. J. Pharmacol. 127, 546.
          Cardenas, A., et al. 1998. Eur. J. Pharmacol. 354, 161.
          Parrino, P.E., et al. 1998. Ann. Thorac. Surg. 66, 733.
          Garvey, E.P., et al. 1997. J. Biol. Chem. 272, 4959.
          Laszlo, F., and Whittle, B.J. 1997. Eur. J. Pharmacol. 334, 99.
          Thomsen, L.L., et al. 1997. Cancer Res. 57, 3300.
          Citation
        • Peyssonnaux, C., et al. 2005. The Journal of Clinical Investigation 115, 1860.